Advances in therapy for CF, such as triple CFTR modulatory therapy with elexacaftor/tezacaftor/ivacaftor (ETI) [10,12,13], have improved life expectancy for pwCF to more than 50 years of age, and the number of adults with CF now exceeds the number of pediatric pwCF [5,10]. This evidence concerns the gene CFTR and cystic fibrosis.